Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, PET, ANW

Heska extends product line with new Element COAGtm Veterinary Analyzer


LOVELAND, Colo., Oct. 31, 2017 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and specialty products, announced today the release of the new Element COAGtm Veterinary Analyzer.

The compact bench top analyzer delivers coagulation and blood typing parameters to complement Heska's Element leading chemistry, hematology, immunodiagnostics blood gas and electrolyte analyzers. Within minutes and with only 100uL of sample, Element COAG delivers accurate PT/aPTT (coagulation), Canine Fibrinogen, Equine Fibrinogen, Canine DEA 1.1 Blood Typing and Feline A/B Blood Typing. Available for purchase or under Heska's unique six-year Reset program, the Element COAG specialty lab analyzer is a "must have" for general practice and high-volume emergency and specialty practice settings.

Steve Eyl, Heska's Executive Vice President, commented, "We are pleased to have been selected by Zoetis, the developer and manufacturer of the product, as the product's distributor in North America. We believe our selection is another indication of Heska's strong relationship with veterinarians in the diagnostics space and another confirmation of our winning momentum. Element COAG is the latest addition to our full Element family of analyzers. In addition to attracting new opportunities in new locations to Heska's Reset subscription, we anticipate a strong Element COAG reception from our thousands of Reset subscription members looking to expand and extend their Reset subscriptions for years to come."

About Heska

Heska Corporation (NASDAQ:HSKA - News) sells advanced veterinary diagnostic and specialty products. Heska's state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, vaccines, local and cloud-based data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company's core focus is on supporting veterinarians in the canine and feline healthcare space. For further information on Heska and its products, visit www.heska.com.

Contact Heska today at 800.464.3752 and visit www.heska.com for more information.

Forward-Looking Statements

This announcement contains forward-looking statements regarding Heska's future financial and operating results. These statements are based on current expectations and are subject to a number of risks and uncertainties. Investors should note that there is an inherent risk in using past results, including trends, to predict future outcomes, including financial results and perceived customer behavior. Factors that could affect the business and financial results of Heska generally include, but are not limited to, the following: risks related to reliance on third parties to develop and manufacture products for Heska; risks related to the commercialization of new products; uncertainties related to attempts to expand into international markets, including, but not limited to, uncertainties related to timing, profitability and currency effects; uncertainties related to Heska's ability to measure and predict trends in the veterinary market; uncertainties related to Heska's ability to measure and predict the effectiveness of commercial relationships; uncertainties related to the future impact of recent business development activity; risks related to Heska's reliance on third-party suppliers, which is substantial; competition; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Quarterly Report on Form 10-Q for the period ended June 31, 2017.

© 2017 Heska. All rights reserved. Element COAG is a registered trademark of Heska Corp. Specifications, prices, design, and availability subject to change without notice. Claims and offers subject to terms and conditions. Contact Heska for details.

SOURCE Heska Corporation


These press releases may also interest you

at 20:31
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

at 19:35
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

at 18:36
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

at 17:55
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...

at 17:53
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit: All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...



News published on and distributed by: